Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to&amp;nbsp;hepatocellular carcinoma

Wei, Minyan; Guo, Xianping; Tu, Liuxiao; Zou, Qi; Li, Qi; Tang, Chenyi; Bao, Chao; Xu, Yang; Wu, Chuanbin

doi:10.2147/ijn.s87011

Cited by 41 publications

(10 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Lactoferrin As a Cargo For Cancer Targetingmentioning

confidence: 99%

“…The use of Lf-loaded liposomes as anti-cancer drug carrier has also been tested [201,202]. In particular, bLf-containing polyethylene glycol (PEG)-modified liposomes have been employed in the targeting of Dox in in vitro and in vivo models of hepatocarcinoma, showing a relevant effect in improving Dox cellular uptake, which was associated to the presence of asialoglycoprotein receptors on cancer cell membrane, and to a significant inhibition of tumor growth in mice bearing HepG2 xenografts compared to mice injected intravenously with the sole Dox-loaded PEGylated liposomes [201]. Moreover, the intravenous injection of Dox-loaded holo-bLf-liposomes in a murine model of breast cancer resulted, along with a high accumulation of the nanocomposites in the tumor site, in tumor suppression and in a higher induction, when compared to mice treated with the sole Dox-loaded liposomes, of hydrogen peroxide conversion to oxygen, due to the release of ferric ions following holo-bLf degradation [202].…”

Section: Lactoferrin As a Cargo For Cancer Targetingmentioning

confidence: 99%

See 1 more Smart Citation

Lactoferrin’s Anti-Cancer Properties: Safety, Selectivity, and Wide Range of Action

et al. 2020

View full text Add to dashboard Cite

Despite recent advances in cancer therapy, current treatments, including radiotherapy, chemotherapy, and immunotherapy, although beneficial, present attendant side effects and long-term sequelae, usually more or less affecting quality of life of the patients. Indeed, except for most of the immunotherapeutic agents, the complete lack of selectivity between normal and cancer cells for radioand chemotherapy can make them potential antagonists of the host anti-cancer self-defense over time. Recently, the use of nutraceuticals as natural compounds corroborating anti-cancer standard therapy is emerging as a promising tool for their relative abundance, bioavailability, safety, low-cost effectiveness, and immuno-compatibility with the host. In this review, we outlined the anti-cancer properties of Lactoferrin (Lf), an iron-binding glycoprotein of the innate immune defense. Lf shows high bioavailability after oral administration, high selectivity toward cancer cells, and a wide range of molecular targets controlling tumor proliferation, survival, migration, invasion, and metastasization. Of note, Lf is able to promote or inhibit cell proliferation and migration depending on whether it acts upon normal or cancerous cells, respectively. Importantly, Lf administration is highly tolerated and does not present significant adverse effects. Moreover, Lf can prevent development or inhibit cancer growth by boosting adaptive immune response. Finally, Lf was recently found to be an ideal carrier for chemotherapeutics, even for the treatment of brain tumors due to its ability to cross the blood-brain barrier, thus globally appearing as a promising tool for cancer prevention and treatment, especially in combination therapies.

show abstract

Section: Lactoferrin As a Cargo For Cancer Targetingmentioning

confidence: 99%

Section: Lactoferrin As a Cargo For Cancer Targetingmentioning

confidence: 99%

Lactoferrin’s Anti-Cancer Properties: Safety, Selectivity, and Wide Range of Action

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Their results demonstrated that the targeting and dual delivery of both drugs gave rise to enhanced therapeutic effects compared to non-targeted or single drug liposomes. Wei et al investigated liposomes made of soybean phosphatidylcholine/cholesterol which was PEGylated to deliver DOX [79]. PEGylation is advantageous as it increases circulation time and avoids rapid clearance by the reticuloendothelial system [80,81].…”

Section: Lipid-based Particlesmentioning

confidence: 99%

“…DOX, also known by one of its trade name Adriamycin, is one of the most common drugs used in liver cancer therapy and in many biomaterial based therapies [58,65,77,79,82,83,93,96,108,109,111]. Besides DOX, taxel-based drugs, such as docetaxel and PTX, are often used in biomaterial based therapies for HCC as well [57,59,87,98].…”

Section: Chemotherapymentioning

confidence: 99%

Liver Cancer: Current and Future Trends Using Biomaterials

Chew

Moscato

George

et al. 2019

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common type of cancer diagnosed and the second leading cause of death worldwide. Despite advancement in current treatments for HCC, the prognosis for this cancer is still unfavorable. This comprehensive review article focuses on all the current technology that applies biomaterials to treat and study liver cancer, thus showing the versatility of biomaterials to be used as smart tools in this complex pathologic scenario. Specifically, after introducing the liver anatomy and pathology by focusing on the available treatments for HCC, this review summarizes the current biomaterial-based approaches for systemic delivery and implantable tools for locally administrating bioactive factors and provides a comprehensive discussion of the specific therapies and targeting agents to efficiently deliver those factors. This review also highlights the novel application of biomaterials to study HCC, which includes hydrogels and scaffolds to tissue engineer 3D in vitro models representative of the tumor environment. Such models will serve to better understand the tumor biology and investigate new therapies for HCC. Special focus is given to innovative approaches, e.g., combined delivery therapies, and to alternative approaches—e.g., cell capture—as promising future trends in the application of biomaterials to treat HCC.

show abstract

“…Moreover, PEGylated doxorubicin in thermosensitive liposomes were formulated in order to differentiate the drug release decreasing tumour growth [ 215 ]. Lactoferrin considered as a target-ligand for hepatocellular carcinoma cells was applied as a modifying agent to PEGylated liposomes encapsulating doxorubicin, showing significantly strong antitumor efficacy [ 216 ].…”

Section: Types Of Nanocarriersmentioning

confidence: 99%

Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses

Sıafaka

Okur

Karavas

et al. 2016

IJMS

160

View full text Add to dashboard Cite

Nanocarriers, due to their unique features, are of increased interest among researchers working with pharmaceutical formulations. Polymeric nanoparticles and nanocapsules, involving non-toxic biodegradable polymers, liposomes, solid lipid nanoparticles, and inorganic–organic nanomaterials, are among the most used carriers for drugs for a broad spectrum of targeted diseases. In fact, oral, injectable, transdermal-dermal and ocular formulations mainly consist of the aforementioned nanomaterials demonstrating promising characteristics such as long circulation, specific targeting, high drug loading capacity, enhanced intracellular penetration, and so on. Over the last decade, huge advances in the development of novel, safer and less toxic nanocarriers with amended properties have been made. In addition, multifunctional nanocarriers combining chemical substances, vitamins and peptides via coupling chemistry, inorganic particles coated by biocompatible materials seem to play a key role considering that functionalization can enhance characteristics such as biocompatibility, targetability, environmental friendliness, and intracellular penetration while also have limited side effects. This review aims to summarize the “state of the art” of drug delivery carriers in nanosize, paying attention to their surface functionalization with ligands and other small or polymeric compounds so as to upgrade active and passive targeting, different release patterns as well as cell targeting and stimuli responsibility. Lastly, future aspects and potential uses of nanoparticulated drug systems are outlined.

show abstract

Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma

Cited by 41 publications

References 49 publications

Lactoferrin’s Anti-Cancer Properties: Safety, Selectivity, and Wide Range of Action

Lactoferrin’s Anti-Cancer Properties: Safety, Selectivity, and Wide Range of Action

Liver Cancer: Current and Future Trends Using Biomaterials

Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses

Contact Info

Product

Resources

About